Clinical Trial: A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07661537) titled 'A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma' on June 16.

Brief Summary: The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: B-cell Non-Hodgkin Lymphoma

Intervention: DRUG: SHR-3079 Injection

SHR-3079 injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Suzhou Suncadia Biopharmaceut...